Neuropathic pain syndromes can be treated with NCP-01 and its autologous stem cell technology, which can treat disorders of the central and peripheral nervous systems. Spinal cord injury, chronic brainstem injury, traumatic brain injury, and peripheral nerve injury are all examples of traumatic injuries and many more
Hemostemix recently granted the global field license of use of NCP-01 and its autologous stem cell therapies to PreCerv Inc. its wholly owned subsidiary to aid patients with peripheral and central nervous system conditions.
UI is a life sciences industry on a mission to show the safety and efficacy of its ibogaine-based drug detox procedure in a planned Canadian Clinical Trial, with the goal of eventually licensing the protocol around the world.
The UI story will be distributed through numerous platforms and audiences by Blue Digital. The expected outcome is increased knowledge of UI's plans to conduct research into the use of ibogaine as part of a continuum of care for opioid addiction and other addictions.
Dr. Sola, a co-founder of Universal Ibogaine and a member of its Board of Directors, has...
Hemostemix disclosed a non-brokered private offering of about 15 million units to shareholders, priced in the context of the market, with each unit consisting of one common share and one common share purchase warrant.